We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.85%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.09B
AUM Growth
+$304M
Cap. Flow
-$377M
Cap. Flow %
-12.21%
Top 10 Hldgs %
47.14%
Holding
153
New
43
Increased
25
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$99.9M
2
ABBV icon
AbbVie
ABBV
+$92.7M
3
LRMR icon
Larimar Therapeutics
LRMR
+$41.5M
4
WBA
Walgreens Boots Alliance
WBA
+$40.8M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$36.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$216M
2
AGN
Allergan Inc
AGN
+$129M
3
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$62.2M
4
NVRO
NEVRO CORP.
NVRO
+$40.5M
5
AERI
Aerie Pharmaceuticals
AERI
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 60.38%
2 Financials 2.52%
3 Technology 0.47%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
76
ProQR Therapeutics
PRQR
$240M
$4.58M 0.15%
209,398
-170,602
-45% -$3.52M
TRIL
77
DELISTED
Trillium Therapeutics Inc.
TRIL
$4.57M 0.15%
+226,064
New +$3.33M
CDNA icon
78
CareDx
CDNA
$2.05B
$4.46M 0.14%
804,000
– –
WINT
79
DELISTED
Windtree Therapeutics Inc
WINT
$4.36M 0.14%
261,407
– –
CCRN icon
80
Cross Country Healthcare
CCRN
$428M
$4.35M 0.14%
+366,724
New +$4.2M
CASM
81
DELISTED
CAS Medical Systems, Inc.
CASM
$4.27M 0.14%
3,200,000
– –
SCYX icon
82
SCYNEXIS
SCYX
$42.4M
$4.09M 0.13%
6,160
-90
-1% -$73.9K
TVTX icon
83
Travere Therapeutics
TVTX
$5.27B
$3.79M 0.12%
+158,223
New +$2.41M
DERM
84
DELISTED
Dermira, Inc.
DERM
$3.55M 0.12%
231,467
+115,200
+99% +$1.94M
SCMP
85
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$3.5M 0.11%
+225,000
New +$3.49M
ASND icon
86
Ascendis Pharma A/S
ASND
$17.1B
$3.47M 0.11%
+200,000
New +$3.64M
STJ
87
DELISTED
St Jude Medical
STJ
$3.29M 0.11%
+50,370
New +$3.35M
NVTA
88
DELISTED
Invitae Corporation
NVTA
$2.79M 0.09%
+166,666
New +$3.09M
PTN
89
Palatin Technologies
PTN
$16.2M
$2.04M 0.07%
1,600
– –
KIN
90
DELISTED
Kindred Biosciences, Inc.
KIN
$1.99M 0.06%
279,204
-73,180
-21% -$504K
IMMU
91
CALL
DELISTED
Immunomedics Inc
IMMU
$1.92M 0.06%
500,000
– –
APYX icon
92
Apyx Medical
APYX
$180M
$1.67M 0.05%
+700,000
New +$2.33M
ACAD icon
93
Acadia Pharmaceuticals
ACAD
$4.38B
$1.61M 0.05%
+49,400
New +$1.7M
LITS
94
Lite Strategy Inc
LITS
$33.6M
$1.44M 0.05%
40,128
-106,866
-73% -$9.57M
PARN
95
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$1.25M 0.04%
253,592
-122,108
-33% -$565K
ILMN icon
96
Illumina
ILMN
$28.2B
$1.19M 0.04%
6,579
+2,467
+60% +$465K
ABEO icon
97
Abeona Therapeutics
ABEO
$399M
$1.1M 0.04%
13,996
-899
-6% -$72.4K
ALKS icon
98
Alkermes
ALKS
$8.79B
$1.07M 0.03%
+17,500
New +$1.2M
AGRX
99
DELISTED
Agile Therapeutics
AGRX
$973K 0.03%
53
– –
MRTX
100
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$965K 0.03%
+32,912
New +$772K
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2015 Portfolio in Review

As of Q1 2015, Deerfield Management held 153 positions worth $3.09B, up 11% from $2.78B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deerfield Management withdrew a net $377M in Q1 2015, closing 29 positions and reducing 27 holdings. Its most notable exit was AUXILIUM PHARAMCEUTICALS INC, an estimated $216M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in AbbVie worth $89.8M.

  • Deerfield Management's largest Q1 2015 buy was AbbVie: 1,534,000 shares worth $89.8M.
  • Deerfield Management added most to AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q1 2015, an estimated $99.9M increase.
  • Deerfield Management's biggest Q1 2015 reduction was Aerie Pharmaceuticals, cutting an estimated $36.3M.
  • Deerfield Management fully exited AUXILIUM PHARAMCEUTICALS INC in Q1 2015, selling an estimated $216M.
  • Deerfield Management's ten largest holdings make up 47% of its $3.09B portfolio in Q1 2015.
  • Deerfield Management opened 43 new positions and closed 29 in Q1 2015.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $3.09B.

Based on Deerfield Management's 13F filing for Q1 2015, filed 15 May 2015.